- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Valion Bio, Inc.: Valion Bio Announces Changes to Management and Board of Directors | 234 | ACCESS Newswire | Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.Lead Asset Positioned for Significant Markets:... ► Artikel lesen | |
| 27.08. | Valion Bio, Inc.: Valion Bio Announces Reverse Stock Split | 478 | ACCESS Newswire | SAN ANTONIO, TX / ACCESS Newswire / August 27, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion Bio" or the "Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock... ► Artikel lesen | |
| 27.08. | Valion Bio announces 1-for-25 reverse stock split | 2 | Investing.com | ||
| 27.08. | Valion Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.08. | Valion Bio mit Führungswechsel und neuer Finanzierung | 2 | Investing.com Deutsch | ||
| 17.08. | Valion Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.08. | Valion Bio, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 13.08. | Valion Bio, Inc.: Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase | 564 | ACCESS Newswire | Potential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government ProcurementFormal review accepted July 22 • Ministry... ► Artikel lesen | |
| VALION BIO Aktie jetzt für 0€ handeln | |||||
| 12.08. | Valion Bio, Inc.: Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury | 899 | ACCESS Newswire | AFRRI/NIAID Program to Advance Safety and Therapeutic Studies in Rapid Sequence; Top-Line Therapeutic Data Expected in Early FallStudy drug delivered • IACUC approval secured • Safety study planned... ► Artikel lesen | |
| 20.07. | Sheba Medical Center to evaluate Valion Bio's Entolimod in trial | 4 | Investing.com | ||
| 20.07. | Sheba Medical Center prüft Entolimod von Valion Bio in klinischer Studie | 1 | Investing.com Deutsch | ||
| 17.07. | Valion Bio, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 14.07. | Valion Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.06. | Valion Bio, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.06. | Valion Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 03.06. | Valion Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | Valion Bio outlines end-2026 Entolimod GMP validation target as NIAID funds GI-ARS BLA-enabling work | 2 | Seeking Alpha | ||
| 14.05. | Valion Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Valion Bio subsidiary secures exclusive NMR platform license | 1 | Investing.com | ||
| 14.05. | Valion Bio, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEARTFLOW | 49,710 | 0,00 % | Heartflow, Inc.: Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half | FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 61,42 | -0,02 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 12,835 | +0,04 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 13,545 | 0,00 % | Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics | Generates $1.3 billion in total revenue, representing 31.6% growth year-over-year Grows Medicare Advantage membership 31.5% year-over-year to approximately 294,100 membersRaises the midpoint of all... ► Artikel lesen | |
| SANARA MEDTECH | 34,700 | -0,06 % | Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited) | FORT WORTH, TX, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," "Sanara MedTech," the "Company," "we," "our" or "us") (Nasdaq: SMTI), a medical technology company focused on developing... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 20,675 | +0,02 % | Privia Health Group, Inc.: Privia Health Announces Appointment of Opella Ernest, M.D. to its Board of Directors | ARLINGTON, Va., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Opella Ernest, M.D. to its Board of Directors, effective September 1, 2026.... ► Artikel lesen | |
| BILLIONTOONE | 99,50 | 0,00 % | Canaccord initiates BillionToOne stock coverage with buy rating | ||
| GENEDX | 87,42 | +0,03 % | GeneDx study shows rapid genome sequencing benefits beyond ICUs | ||
| BETA BIONICS | 19,920 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance | IRVINE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 13,640 | 0,00 % | Aveanna Healthcare Stock Offers Everything Investors Want as Shares Hit New All-Time High | ||
| PROGYNY | 26,630 | +0,08 % | Progyny stock price target maintained at $31 by Citizens on new offering | ||
| ADAPTHEALTH | 6,445 | +0,39 % | Morning Market Movers: Ameresco, Inno Holdings, AdaptHealth, Ibotta See Big Swings | OTTAWA (dpa-AFX) - At 7:50 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| KESTRA MEDICAL TECHNOLOGIES | 25,140 | 0,00 % | Kestra Medical Technologies, Ltd.: Kestra Medical Technologies to Report First Quarter Fiscal 2027 Financial Results on September 14 | ||
| PROCEPT BIOROBOTICS | 21,380 | 0,00 % | PROCEPT BioRobotics Reports First Quarter 2026 Financial Results | SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| GUARDIAN PHARMACY SERVICES | 40,010 | 0,00 % | Guardian Pharmacy acquires assets from Nautilus Pharmacy |
VALION BIO INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von +0,010 (+0,36 %) liegt der Kurs bei 2,810 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VALION BIO INC finden Sie auf Wallstreet Online.